Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score
Abstract Previous clinic models for patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) mainly focused on the overall survival, whereas a simple-to-use tool for predicting the response to the first TACE and the management of risk classification before TACE a...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-10-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-023-00803-2 |
| _version_ | 1827710352314335232 |
|---|---|
| author | Jia-Wei Zhong Dan-Dan Nie Ji-Lan Huang Rong-Guang Luo Qing-He Cheng Qiao-Ting Du Gui-Hai Guo Liang-Liang Bai Xue-Yun Guo Yan Chen Si-Hai Chen |
| author_facet | Jia-Wei Zhong Dan-Dan Nie Ji-Lan Huang Rong-Guang Luo Qing-He Cheng Qiao-Ting Du Gui-Hai Guo Liang-Liang Bai Xue-Yun Guo Yan Chen Si-Hai Chen |
| author_sort | Jia-Wei Zhong |
| collection | DOAJ |
| description | Abstract Previous clinic models for patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) mainly focused on the overall survival, whereas a simple-to-use tool for predicting the response to the first TACE and the management of risk classification before TACE are lacking. Our aim was to develop a scoring system calculated manually for these patients. A total of 437 patients with hepatocellular carcinoma (HCC) who underwent TACE treatment were carefully selected for analysis. They were then randomly divided into two groups: a training group comprising 350 patients and a validation group comprising 77 patients. Furthermore, 45 HCC patients who had recently undergone TACE treatment been included in the study to validate the model’s efficacy and applicability. The factors selected for the predictive model were comprehensively based on the results of the LASSO, univariate and multivariate logistic regression analyses. The discrimination, calibration ability and clinic utility of models were evaluated in both the training and validation groups. A prediction model incorporated 3 objective imaging characteristics and 2 indicators of liver function. The model showed good discrimination, with AUROCs of 0.735, 0.706 and 0.884 and in the training group and validation groups, and good calibration. The model classified the patients into three groups based on the calculated score, including low risk, median risk and high-risk groups, with rates of no response to TACE of 26.3%, 40.2% and 76.8%, respectively. We derived and validated a model for predicting the response of patients with HCC before receiving the first TACE that had adequate performance and utility. This model may be a useful and layered management tool for patients with HCC undergoing TACE. |
| first_indexed | 2024-03-10T17:36:45Z |
| format | Article |
| id | doaj.art-a43f48439f8643cd97517e9df35aadc5 |
| institution | Directory Open Access Journal |
| issn | 2730-6011 |
| language | English |
| last_indexed | 2024-03-10T17:36:45Z |
| publishDate | 2023-10-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj.art-a43f48439f8643cd97517e9df35aadc52023-11-20T09:50:32ZengSpringerDiscover Oncology2730-60112023-10-0114111810.1007/s12672-023-00803-2Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF scoreJia-Wei Zhong0Dan-Dan Nie1Ji-Lan Huang2Rong-Guang Luo3Qing-He Cheng4Qiao-Ting Du5Gui-Hai Guo6Liang-Liang Bai7Xue-Yun Guo8Yan Chen9Si-Hai Chen10Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Fengcheng People’s HospitalMedical Imaging Department, The First Affiliated Hospital of Nanchang UniversityDepartment of Interventional Medicine, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityDepartment of Interventional Medicine, The First Affiliated Hospital of Nanchang UniversityDepartment of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang UniversityAbstract Previous clinic models for patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) mainly focused on the overall survival, whereas a simple-to-use tool for predicting the response to the first TACE and the management of risk classification before TACE are lacking. Our aim was to develop a scoring system calculated manually for these patients. A total of 437 patients with hepatocellular carcinoma (HCC) who underwent TACE treatment were carefully selected for analysis. They were then randomly divided into two groups: a training group comprising 350 patients and a validation group comprising 77 patients. Furthermore, 45 HCC patients who had recently undergone TACE treatment been included in the study to validate the model’s efficacy and applicability. The factors selected for the predictive model were comprehensively based on the results of the LASSO, univariate and multivariate logistic regression analyses. The discrimination, calibration ability and clinic utility of models were evaluated in both the training and validation groups. A prediction model incorporated 3 objective imaging characteristics and 2 indicators of liver function. The model showed good discrimination, with AUROCs of 0.735, 0.706 and 0.884 and in the training group and validation groups, and good calibration. The model classified the patients into three groups based on the calculated score, including low risk, median risk and high-risk groups, with rates of no response to TACE of 26.3%, 40.2% and 76.8%, respectively. We derived and validated a model for predicting the response of patients with HCC before receiving the first TACE that had adequate performance and utility. This model may be a useful and layered management tool for patients with HCC undergoing TACE.https://doi.org/10.1007/s12672-023-00803-2Hepatocellular carcinomaTransarterial chemoembolizationFirst responseIndividual prediction |
| spellingShingle | Jia-Wei Zhong Dan-Dan Nie Ji-Lan Huang Rong-Guang Luo Qing-He Cheng Qiao-Ting Du Gui-Hai Guo Liang-Liang Bai Xue-Yun Guo Yan Chen Si-Hai Chen Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score Discover Oncology Hepatocellular carcinoma Transarterial chemoembolization First response Individual prediction |
| title | Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score |
| title_full | Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score |
| title_fullStr | Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score |
| title_full_unstemmed | Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score |
| title_short | Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score |
| title_sort | prediction model of no response before the first transarterial chemoembolization for hepatocellular carcinoma tacf score |
| topic | Hepatocellular carcinoma Transarterial chemoembolization First response Individual prediction |
| url | https://doi.org/10.1007/s12672-023-00803-2 |
| work_keys_str_mv | AT jiaweizhong predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT dandannie predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT jilanhuang predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT rongguangluo predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT qinghecheng predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT qiaotingdu predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT guihaiguo predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT liangliangbai predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT xueyunguo predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT yanchen predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore AT sihaichen predictionmodelofnoresponsebeforethefirsttransarterialchemoembolizationforhepatocellularcarcinomatacfscore |